Trial Profile
A randomised, open-label study to compare the effect of new-onset therapy with PEGASYS [peginterferon alfa 2a], and continuation therapy with adefovir dipivoxil or lamivudine, on viral response in patients with chronic hepatitis B pre-treated with adefovir dipivoxil or lamivudine
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Mar 2016
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Adefovir dipivoxil; Lamivudine
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Roche
- 23 Feb 2010 Planned number of patients changed from 140 to 14 as reported by Roche record.
- 17 Jul 2008 New trial record.